Stemedica Cell Technologies Revenue and Competitors
Estimated Revenue & Valuation
- Stemedica Cell Technologies's estimated annual revenue is currently $6.2M per year.
- Stemedica Cell Technologies's estimated revenue per employee is $155,000
Employee Data
- Stemedica Cell Technologies has 40 Employees.
- Stemedica Cell Technologies grew their employee count by 48% last year.
Stemedica Cell Technologies's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | CHIEF REGULATORY & CLINICAL DEVELOPMENT OFFICER | Reveal Email/Phone |
3 | Chief Regulatory and Clinical Development Officer | Reveal Email/Phone |
4 | Chief Medical Officer | Reveal Email/Phone |
5 | Chief Technology Officer | Reveal Email/Phone |
6 | VP, Investor Relations | Reveal Email/Phone |
7 | SVP, Corporate Administration & Investor Relations | Reveal Email/Phone |
8 | VP, Clinical Development | Reveal Email/Phone |
9 | Director Laser Stem Cell | Reveal Email/Phone |
10 | Senior Materials Manager | Reveal Email/Phone |
Stemedica Cell Technologies Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.4M | 70 | -8% | $53M | N/A |
#2 | $32.4M | 167 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.8M | 18 | 13% | N/A | N/A |
#5 | $0.8M | 5 | -50% | N/A | N/A |
#6 | $0.8M | 10 | 0% | N/A | N/A |
#7 | $14M | 90 | -12% | N/A | N/A |
#8 | $0.4M | 336 | 10% | $236.7M | N/A |
#9 | $4.8M | 62 | -74% | $160M | N/A |
#10 | $3.7M | 24 | -8% | N/A | N/A |
What Is Stemedica Cell Technologies?
Stemedica Cell Technologies, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of progenitor cell and protein therapeutics for underserved medical conditions. Stemedica has developed a proprietary manufacturing technology platform that produces allogeneic progenitor cell products with intellectual property protection under a low-oxygen, low-tension environment in a cGMP-compliant manufacturing facility. The company's lead drug candidate, ischemia-tolerant mesenchymal stem cells, or itMSCs, is an allogeneic progenitor cell therapy currently in clinical development for the treatment of ischemic stroke and Alzheimer’s disease. The company’s second drug candidate, ischemia-tolerant neural progenitor cells, or itNSCs, is an allogeneic cell therapy currently in development for spinal cord injury. In addition, Stemedica is developing progenitor multi-cell therapy (itMSCs and itNSCs) for ischemic stroke and progenitor cell and protein combination therapy for Alzheimer’s disease. More information on Stemedica may be found at www.stemedica.com.
keywords:N/A
N/A
Total Funding
40
Number of Employees
$6.2M
Revenue (est)
48%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in San Diego
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $4.5M | 40 | -17% | N/A |
#2 | $4.4M | 40 | -13% | $2.2M |
#3 | $5.8M | 40 | -11% | N/A |
#4 | $4.6M | 40 | N/A | N/A |
#5 | $5M | 40 | -11% | $4.5M |